Ropinirole
Nonergot Dopamine Agonist
NADAC/unit
$0.0426
No Shortage
Tier 1: 296.7%
13 Manufacturers
91 ANDAs
a non-ergoline dopamine agonist indicated for the treatment of Parkinson’s disease (PD) and moderate-to-severe primary Restless Legs Syndrome (RLS). (1.1, 1.2). 1.1 Parkinson's Disease Ropinirole t....
Market Intelligence
2023-03-08 Class II Recall: Accord Healthcare, Inc.
2023-03-08 Class II Recall: Accord Healthcare, Inc.
2023-03-08 Class II Recall: Accord Healthcare, Inc.
2023-03-08 Class II Recall: Accord Healthcare, Inc.
2023-03-08 Class II Recall: Accord Healthcare, Inc.
Generic Manufacturers
ACCORD HEALTHCARE INCACTAVIS ELIZABETH LLCALEMBIC LTDALEMBIC PHARMACEUTICALS LTDCHARTWELL RX SCIENCES LLCDR REDDYS LABORATORIES LTDELITE LABORATORIES INCGLENMARK PHARMACEUTICALS LTDMLV PHARMA LLCORBION PHARMACEUTICALS PRIVATE LTDPRINSTON PHARMACEUTICAL INCSANDOZ INCZYDUS LIFESCIENCES LTD
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.